Enclave Advisors LLC Sells 31 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Enclave Advisors LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.4% during the 2nd quarter, Holdings Channel reports. The firm owned 457 shares of the biopharmaceutical company’s stock after selling 31 shares during the period. Enclave Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $240,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management increased its stake in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Curat Global LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.5%

Regeneron Pharmaceuticals stock opened at $563.90 on Monday. The stock has a market cap of $59.77 billion, a P/E ratio of 14.21, a P/E/G ratio of 1.80 and a beta of 0.35. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,070.00. The company’s 50-day moving average price is $569.79 and its two-hundred day moving average price is $569.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $11.56 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Morgan Stanley reissued an “overweight” rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Finally, Truist Financial lowered their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.